What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Surgery
His primary areas of study are Surgery, Colorectal cancer, Internal medicine, Oncology and Cancer.
His research integrates issues of Clinical trial and Palliative care in his study of Surgery.
His Colorectal cancer study integrates concerns from other disciplines, such as Rectum, Randomized controlled trial and Fluorouracil.
His research on Internal medicine frequently connects to adjacent areas such as Gastroenterology.
His work carried out in the field of Oncology brings together such families of science as Cetuximab, Epidemiology, Relative risk, Cumulative dose and Adjuvant therapy.
Within one scientific family, Bengt Glimelius focuses on topics pertaining to Cohort study under Cancer, and may sometimes address concerns connected to Pediatrics.
His most cited work include:
- Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial (1453 citations)
- Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial (1453 citations)
- Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial (1002 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Colorectal cancer, Oncology, Surgery and Cancer.
His work in Internal medicine covers topics such as Gastroenterology which are related to areas like Phases of clinical research.
The concepts of his Colorectal cancer study are interwoven with issues in Rectum, Chemoradiotherapy and Randomized controlled trial.
His Oncology research incorporates themes from Irinotecan, Capecitabine, KRAS, Hazard ratio and Cohort.
His Surgery research incorporates elements of Clinical trial and Palliative care.
He has included themes like Preoperative care and Total mesorectal excision in his Radiation therapy study.
He most often published in these fields:
- Internal medicine (57.41%)
- Colorectal cancer (51.31%)
- Oncology (39.12%)
What were the highlights of his more recent work (between 2015-2021)?
- Colorectal cancer (51.31%)
- Internal medicine (57.41%)
- Oncology (39.12%)
In recent papers he was focusing on the following fields of study:
Bengt Glimelius spends much of his time researching Colorectal cancer, Internal medicine, Oncology, Chemotherapy and Radiation therapy.
His study in Colorectal cancer is interdisciplinary in nature, drawing from both Adjuvant chemotherapy, Chemoradiotherapy, Surgery and Clinical trial.
As part of his studies on Surgery, Bengt Glimelius often connects relevant subjects like Total mesorectal excision.
His work in Oxaliplatin, Randomized controlled trial, Hazard ratio, Cancer and Cohort is related to Internal medicine.
His work on Adjuvant as part of his general Oncology study is frequently connected to In patient, thereby bridging the divide between different branches of science.
His studies in Radiation therapy integrate themes in fields like Neoadjuvant therapy and Stage.
Between 2015 and 2021, his most popular works were:
- Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib the LAP07 randomized clinical trial (428 citations)
- Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial (169 citations)
- The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. (94 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Surgery
Bengt Glimelius mainly focuses on Internal medicine, Colorectal cancer, Oncology, Surgery and Chemoradiotherapy.
His Colorectal cancer research is multidisciplinary, relying on both Locally advanced, Radiation therapy, Chemotherapy, Young adult and Survival rate.
Bengt Glimelius combines subjects such as Statement, Cancer and Expert consensus with his study of Radiation therapy.
His Oncology research includes themes of Microsatellite instability, Proportional hazards model, Stage, Stage ii and Confounding.
In his work, Clinical endpoint is strongly intertwined with Total mesorectal excision, which is a subfield of Surgery.
His Chemoradiotherapy study combines topics in areas such as Neoadjuvant therapy, Chemo-radiotherapy, Progression-free survival and Rectal cancer surgery.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
